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Marfan syndrome. which is characterized bymanifestations in the skeletal, ocular and cardiovascular systems. isoneof the most common inherited 
connective-tissue disorders. The independently pcrformcd genetic assignment ofthe Marfan locus and classical biochemical nd immunohistochcm- 
ical analyses complemented ach other in the search for the Marfan gene defect and in 1991 the fibrillin gene in chromosome I5 was identified 
as the Marfan gene. So far, three mutations leading to the Marfan phenotype have been reported in this gene coding for a microlibrillar Protein. 
The available data suggests a wide spectrum of different mutations of Rbrillin and although mutations of the fibrillin gene account for the majority 
of Mat-fan cases, evidence also exists for locus heterogeneity in a minority of Marfnn cases, 
Mttrfan syndrome: Fibrillin; FBNI; Chromosome I5 
1. INTRODUCTION 
Marfan syndrome is an autosomal dominant connec- 
tive-tissue disorder characterized by skeletal, cnrdiovas- 
cular and ocular manifestations [l]. Many of the fea- 
tures of the syndrome occur with variable frequencies 
in the general population, but when combined, consti- 
tute the systemic disorder called Marfan syndrome. Al- 
though Marfan syndrome was first observed almost 100 
years ago, it was not until in the 1950’s when this syn- 
drome was identified as an inherited connective-tissue 
disease and precisely clinically described [2]. Two major 
symptoms, weakness of the wall of the aorta and dislo- 
cation of the lens were so characteristic for the syn- 
drome that Dr McKusick wrote: ‘What the suspensory 
ligament of the lens has in common with the media of 
the aorta is obscure. If known, the basic defect of syn- 
drome might be understood’ [3]. This prediction turned 
out to be wise and foreseeing. The independently per- 
formed genetic assignment of the Marfan locus and 
classical biochemical and immunohistochemical analy- 
ses of patients’ fibroblasts ideally complemented each 
other in the search for the defective gene in Marfan 
syndrome and resulted in the identification of fibrillin 
gene as this Marfan gene (Fig. 1) [4]. A new era started 
for both basic scientists and clinicians interested in Mar- 
fan syndrome: specific mutations can be identified in 
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patients, diagnostic tests can be offered for family mem- 
bers at the presymptomatic age and the question of 
genetic heterogeneity of this phenotypically highly vari- 
able syndrome can finally be answered. 
2. PHENOTYPIC FEATURES OF MARFAN SYN- 
DROME 
Marfan syndrome occurs with an estimated preva- 
lence of l:lOOOO, without racial or ethnic predilection 
[I]. 1 S-308 of the patients are sporadic and thus repre- 
sent new mutations [l,S]. The penetrance is considered 
complete, although the level of expression of the Mar- 
fnn gene varies widely. 
Skeletal symptoms of Marfan syndrome include in- 
creased height, disproportionally long limbs and digits 
2nd anterior chest deformity, and the typical ocular 
findings include myopia and subluxation of the lenses. 
The most serious manifestations of the disorder occur 
in the cardiovascular system: mitral valve prolapse and 
dilatation of the aortic root which may progress to aor- 
tic dissection, the cause of precocious mortality of Mar- 
fan patients [l]. 
3. BIOCHEMICAL STUDIES ON MARFAN SYN- 
DROME 
The fundamental defect underlying Marfan syn- 
drome was under intensive investigation i  many labo- 
ratories over the past decennia but the search proved 
frustratingly difficult. To explain the weakness of the 
116 
Volume 307, number 1 FEBS LE-ITERS July 1992 
aortic wall of the patients, the investigators studied dif- 
ferent types of collagens, proteoglycans, elastin and 
elastin-associated proteins. This approach was justified 
because the early histological studies had demonstrated 
degeneration ofelastic lamellae as well as an increase in 
collagenous tissue in samples of aortic tissue from Mar- 
fan syndrome patients [2]. 
3.1. Findings OIZ collagens 
There was much indirect evidence supporting the idea 
of defects in the cc,llagen genes of Marfan patients [6]. 
The data included decreased amounts of type I collagen 
in aortic tissue, increased hydroxyproline content of the 
urine of Marfan patients and the increased rate of colla- 
gen synthesis by their fibroblasts suggesting an in- 
creased rate of collagen turnover in Marfan syndrome. 
This enhanced rate of turnover was supported by re- 
ports on a deficiency in chemically stable mature cross- 
links of collagen in Marfan patients. 
A specific finding in type I collagen was demonstrated 
in one patient with somewhat atypical features of the 
Marfan syndrome. In her skin and aorta, together with 
normally migrating proa2(l)collagen chains, a popula- 
tion of chains with an increased apparent molecular 
weight was observed on SDS-PAGE [7,8]. Later, a 
heterozygote single base mutation converting a highly 
conserved AI@’ to Glu (R618Q) in the triple helical 
domain of procC(I)collagen was established [9]. The 
same mutation could not be seen in the DNA of 52 
control individuals or 17 other, non-related Marfan in- 
dividuals. This would suggest that the nucleotide 
change was not a common polymorphism, but neither 
would it be the general cause of Marfan syndrome. 
3.2. Jkdings on elastitl and proteo&um 
Analogous to the search for collagen defects in Mar- 
fan syndrome, studies were carried out to search for 
abnormalities in other connective tissue components [G]. 
In two studies, exceptionally ow amounts of desmosine 
and isodesmosine, the cross-linking amino acids of 
elastin, were observed in aortic samples of Marfan pa- 
tients. Observations on connective tissue protcoglycans 
included increased biosynthesis of hyaluronic acid by 
Marfan fibroblasts and a drastically reduced steady 
state level of decorin mRNA in about one third of Mar- 
fan fibroblast cultures studied [G, lo]. 
All these results on collagens, elastin or proteogly- 
cans were once thought to explain the basic defect un- 
derlying Marfan syndrome but they all represented 
findings either secondary to the basic defect or they 
were found in only a few Marfan individuals and pro- 
vided no explanation for the molecular defect in the 
majority of patients. 
3.3. Findings on u microfibril[ur protein, fibriih 
In 1986 a new extracellular matrix glycoprotein, fi- 
brillin had been identified and characterized [ll], Its 
Fig. 1. The pathway t&Ii in the search for the defect underlying 
Marfan syndrome. (MFS, Marfan syndrome; CHR, chromosome) 
tissue distribution, including aorta and suspensory liga- 
ment of the lens, and location in elastic tissue made it 
an excellent candidate as the defective agent in Marfan 
syndrome. By using indirect immunofluorescence and 
several monoclonal antibodies against he fibrillin poly- 
peptidc, a deficiency of fibrillin fibers in skin sections 
and fibroblast cultures of Marfan patients was demon- 
strated [!2]. Furthermore, the deficient immunofluores- 
cence pattern of fibrillin co-segregated with the disease 
in nine Marfan families. In one exceptional patient with 
clinical findings of Marfan syndrome predominantly 
manifest on the left side of the body, a striking differ- 
ence in the fibrillin immunofluorescence was observed 
both in skin sections and in corresponding fibroblast 
cultures derived from the left (decrease of fibrillin) and 
right sides (normal fibrillin) of the body [!3]. 
To verify these results and to test the consistency of 
the fibrillin deficiency in Marfan syndrome, fibroblasts 
and skin sections of Marfan individuals, patients with 
other connective tissue diseases as well as controls were 
analyzed with indirect immunofluorescence analyses 
using monoclonal antibodies against librillin [!4]. In 
this study, 24 out of 27 Marfan syndrome patients were 
correctly identified as having the syndrome. Of the three 
misclassified patients, two were studied only by skin 
immunostaining, an assay which shows fibrillin defi- 
ciency in only about 75% of Marfan patients. Interesl- 
ingly, fibrillin immunofluorescencc analysis of both the 
skin sections and fibroblasts of the third misclassified 
patient, with typical features of the syndrome, revealed 
normal fibrillin immunofluorescence staining. How- 
ever, he! fibroblasts produced two species of 
proa2(I)collagen chains: in addition to the normal 
chains, there were also abnormal, slowly migrating 
chains quite similar to those reported earlier [7,8]. All 
13 normal individuals as well as 19 out of 25 patients 
with other connective tissue disorders were correctly 
classified as ‘non-Marfan’ in this single blind study. 
To concluile, deficiency in the fibriliin immunofluo- 
rescence pattern was almost a constant finding when 
cultured fibroblasrs and/or skin sections of Marfan pa- 
tients were studied. From al! the reported biochemical 
and immunohistochemical findings reported through 
the decennia, these were the most promising and 
strongly suggested that deficient microfibrillar flbers 
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were intimately coupled to the basic defect causing Mar- 
fan syndrome. 
4. THE LINKAGE APPROACH 
While some groups studied fibrillin in relation to 
Marfan syndrome, other investigators seized the possi- 
bilities of finding the Marfan locus using linkage analy- 
ses and polymorphic markers localized either in or in 
the vicinity of candidate genes or randomly in the 
human genome. The latter markers are utilized in the 
approach called positional cloning, the starting point of 
which is not a known protein and the search is not 
focused on defects in this protein or the gene coding for 
the corresponding polypeptide chain. Instead, DNA of 
patients and their family members is analyzed directly 
and the goal is to first find the chromosomal location 
of the disease gene. Once the locus is established and the 
defective gene in this region defined, the genetic ode is 
used to decipher the normal and mutated polypeptide 
chain encoded by the gene. 
4.1. Linkage studies tc candidate genes 
In the case of Marfan syndrome the linkage approach 
was initiated by studying the inheritance pattern of can- 
didate genes in Marfan pedigrees. Since several bio- 
chemical studies had indicated defects in one of the 
fibril-forming collagens, these were the first to be stud- 
ied. However, several linkage studies demonstrated re- 
combinations between Marfan syndrome and polymor- 
phic markers in or close to both genes coding for type 
I procollagen chains, the gene coding for type 111 pro- 
collagen and, not surprisingly, the gene coding for carti- 
lage-specific type II procollagen [15-181. In other 
words, a defect in any of these genes was in practice 
excluded as the primary cause of the disorder. 
4.2. Random hkage approach 
The first trial towards positional cloning of the Mar- 
fan gene was an exclusion map of chromosome 2. Alto- 
gether 50 CM of the long arm of chromosome 2, includ- 
ing several genes coding for extracellular matrix compo- 
nents, was excluded as the site of the Marfan mutation 
[l91. 
In the next phase, an international collaborative 
study was formed to combine linkage data from nine 
laboratories in five countries and to produce an exclu- 
sion map of Marfan syndrome [20]. Individual labora- 
tories had independently screened different sets of 
markers including both candidate loci and random pol- 
ymorphisms in their own Marfan pedigrees. The linkage 
data combined information from 75 loci on 18 auto- 
somes and excluded 75% of the genome as likely loca- 
tions of the Marfan gene. This map suggested that the 
Marfan gene is located on chromosome 5, 6q, 8, 9p, 
lop, 13, 15, 17p, 2Op, 21, or 22. 
Encouraged by this study, we began to study Finnish 
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families for genetic linkage to random polymorphic 
markers on several chromosomes and in 1990 reported 
the linkage of Marfan syndrome to three markers on 
chromosome 15 in five Finnish families [21]. The link- 
age of Marfan syndrome to this chromosomal area was 
soon confirmed in American and British families sug- 
gesting that the original finding was not specific for the 
genetically isolated Finnish population [22,23]. 
The established linkage to chromosome 15 made it 
possible for the first time to use statistical genetic heter- 
ogeneity analyses in an international collection of Mar- 
fan famiiies. No evidence for locus heterogeneity was 
found underlying the disease when classical Marfan 
families from England, Finland, Scotland, Switzerland 
and the United States were studied [243. The studied 
families all had the classical type of Marfan syndrome 
but the material also included families with only mild 
ocular findings as well as families with ocular findings 
as the major symptom. Other groups have recently pub- 
lished similar data on another collection of Marfan fam- 
ilies [25,26]. To date, the only Marfan family that is 
reported not to be linked to the Marfan region in chro- 
mosome 15, is a large French pedigree, in which all 
affected individuals fulfill the criteria set for Marfan 
syndrome, but do not have subluxation of the lenses 
[25]. 
5. MARFAN MUTATIONS 
5.1. FiLwillin mutariom and their conseqlteltccs 
The relationship between the Marfan syndrome locus 
on chromosome 15 and the most specific biochemical 
finding so far available, the fibrillin deficiency [l4] was 
soon elucidated: after partial cloning of the fibrillin 
cDNA, the gene coding for fibrillin (FBN 1) was, by in 
situ hybridization, localized to the long arm of chromo- 
some 15 at band 21 .l [27,28]. Moreover, a gene on 
chromosome 5(FBN2) demonstrating a high degree of 
homoiogy to tibriliin on chromosome 15 (FBNl) was 
linked to the Marfan syndrome-related disorder. con- 
genital contractural arachnodactyly in two families, this 
providing further support for the importance of fibrillin 
in the pathogenesis of Marfan syndrome [27]. Soon 
after that the first mutation in the FBNl gene in a 
Marfan patient was reported: amissense point mutation 
substituting Pro for Arg2”’ (R239P) found in two unre- 
lated severely affected 17- and 19-year-old sporadic 
Marfan patients [43. The fibrillin cDNA sequence had 
revealed that the corresponding polypeptide chain con- 
tains at least 34 consecutive six-cysteine repeats homol- 
ogous to those found in the ECiF-precursor molecule 
and suggested to stabilize the fibrillin molecules [29]. 
The R239P mutation occurred in a conserved amino 
acid within such a six-cysteine motif suggesting that the 
mutation occurred at a functionally significant site of 
the polypeptide chain. 
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Fig. 2. A schematic representation f the normal fibrillin polypeptidc chain as well as the predickl polypeptide chains mused by the three reported 
mutalions [4.30]. TWO types of repelhive molifs have been idcntilied in the dbrillin sequence, a G-cysteine motif homologous to that found in the 
EGF-precursor ~noleculc and PII tl-cyskinc motif homologous to a motif seen in TGF#I molecules [29]. (Tbc astefisk (*) indicates aG.to.C point 
mulalion, Arg, argininc: Pro, proline; Trp. lryplophan; Del, deletion; aas. amino acids; Cys, cysteine). Modified form Maslen et a]. [29]. 
To date, two other mutations of FBNI gene have 
been reported in Marfan patients. We found a 366 bp 
deletion of fibrillin mRNA predicting a polypeptide 
chain 122 amino acids shorter than normal in a 4%year- 
old British male [30]. This mutation was shown to co- 
segregate with the disease in his family in which Marfan 
syridrome had been diagnosed in three generations. The 
deleted area contained three complete six-cysteine re- 
peat motifs (see above). The consequences of a mutation 
in fibrillin gene were demonstrated for the first time also 
at the polypeptide level. The fibroblasts of this patient 
were shown to secrete two species of fibrillin polypep- 
tide chains: in addition to a polypeptide chain popula- 
tion of normal size. there were also chains of about I5 
kDa shorter, corresponding to the mutated polypeptide 
population. 
The third detected mutation was a heterozygotic G- 
to-A transition at nucleoride 5574 found in the cDNA 
of a %-year-old sporadic Finnish Marfan patient [30]. 
The consequence of this mutation was the substitution 
of a stop codon for Trp”5n (WlS58) predicting the ter- 
mination of the flbrillin polypeptide chain 116 amino 
acids too early. Unlike the protein analyses of the fl- 
broblasts of the patient with the deletion, immunopre- 
cipitation analyses of the medium of this patient’s fi- 
broblasts using fibrillin-specific antibodies failed to de- 
tect a shortened flbrillin polypeptide chain. 
Fig. 2 shows a schematic illustration of the normal 
fibrillin polypeptide chains as well as the polypeptide 
chains predicted to result from the three mutations re- 
ported [4,30]. The true biological consequences of these 
mutations can only be speculated. Like most other Mar- 
fan cell lines, immunofluorescence of fibroblasts from 
these patients displayed reduced amounts of fibrillin 
fibers. Possible explanations include the reduced syn- 
thesis and fibrillogenesis of fibrillin due to a mutation 
iii one allele or an amplified deleterious effect on fibril- 
logenesis due to the secretion and co-polymerization of
the mutant gene product with normal fibrillin. The lat- 
ter mechanism is called GrGt<li> suic& dir2 occurs in 
certain type I procollagen mutations resulting in os- 
teogenesis imperfecta: the presence of abnormal 
proachains interferes with normal triple helical assem- 
bly and results in the degradation of not half but three 
quarters of the synthesized molecules [6]. 
To approach the question of genetic heterogeneity of 
Marfan mutations, we screened DNA samples of 61 
unrelated Marfan patients representing both sporadic 
and familial cases from Belgium, Finland, The Nether- 
lands, Sweden, Switzerland, the United Kingdom and 
the United States for all three reported mutations but 
did not identify any of these mutations in any other 
patients [30]. Consequently, most Marfan mutations 
will probably be specific for each family excluding the 
possibility of a generally applicable diagnostic DNA 
test. 
5.2. Heterogerzeity of Matfan rotations and DNA di- 
ugttostics 
The combination of biochemical and molecu!ar be- 
netic approaches resulted in the elucidation of the mo- 
lecular defect underlying the Marfan syndrome. FBNl 
and FBN2 together with a third homologous gene, fi- 
brillin in chromosome 17 (FBN3) constitute a possibly 
expanding ene family [31]. It is now known that con- 
genital contractural arachnodactyly is most probably 
caused by mutations in FBN2 and a definitive majority 
of Marfan syndrome cases are caused by mutations in 
FBNI. There are, however, some exceplions to this. A 
mutation in the proa2(I)collagen gene causes Marfan 
syndrome in a patient with somewllat atypical Marfan 
syndrome patient [9]. A finding suggesting a similar 
defect in proa2(I)collagen gene has been reported aiso 
in another case, a patient ‘misdiagnosized’ with fibrillin 
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immunofluorcscence analysis (see above) [121. Further, 
in one family in which Marfan syndrome and polycystic 
kidney disease are co-segregating, both disorders have 
been linked to polymorphic markers flanking the poly- 
cystic kidney disease locus in chromosome 16 [32]. 
Linkage studies have also indicated that a large French 
pedigree demonstrates an exclusion of linkage to chro- 
mosome IS markers [25]. Whether these Marfan cases 
are caused by mutations in fibrillin genes other than 
FBNl or FBN2, or whether they are caused by defects 
ir? genes coding for some other extracellular matrix pro- 
teins, will be elucidated in the future. 
All existing data on the number of sporadic cases in 
Marfan syndrome, the degree of clinical variability in 
Marfan syndrome and screening of the known muta- 
tions from other patients’ samples predict a spectrum of 
different mutations in Marfan syndrome. The current 
picture of Marfan syndrome is thus a variety of muta- 
tions in FBNl with the still existing possibility of ge- 
netic heterogeneity. This does not stimulate high hopes 
for generally applicable DNA diagnostics for this dis- 
ease. In sporadic Marfan cases, the immunolluores- 
cence analyses detecting fibrillin fibers in fibroblzst cul- 
tures is perhaps currently the most reliable diagnostic 
laboratory test. In the majority of Marfan families in- 
tragenic polymorphic markers of FBNl can be used for 
presymptomatic diagnostics of young family members, 
although with caution, due to the exceptions listed 
above. Identification of fibrillin mutations in Marfan 
patients has just started and already in near future we 
will learn if Marfan mutations will be enriched to some 
regions of the large fibrillin gene, a phenomenon which 
would create possibilities to develop more widely appli- 
cable diagnostic test. 
Identification of Marfan mutations and careful re- 
porting of the corresponding clinical phenotypes will in 
the foreseeable future help us to understand the impor- 
tant genotype-phenotype r lationships. This under- 
standing is especially interesting in the case of Marfan 
syncirome. It is not only one of the most common inher- 
ited connective-tissue disorders, but several features of 
the phenotype are common among the general popula- 
tion. Consequently, the detailed knowledge of the mo- 
lecular biology of Marfan syndrome and related disor- 
ders will without doubt provide new insights also into 
the various forms of more common connective tissue 
disorders, for example aortic aneurysms, myopia and 
mitral valve prolapse. 
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